ACIU AC IMMUNE SA

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

  • AC Immune to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases
  • Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2025) showcasing the diversity of the company’s precision medicine pipeline

Lausanne, Switzerland, March 25, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) taking place in Vienna, Austria, on April 1 – 5, 2025. AC Immune will host an industry symposium highlighting advances in the clinical development of active immunotherapies featuring key opinion leaders, industry experts and AC Immune leadership.

Industry Symposium: Unlocking active immunotherapy for tailored prevention strategies in neurodegenerative diseases



Session Date/Time: Wednesday, April 2, 2025, at 8:40 – 10:40 am CET

Location: Hall A

Opening and Closing Remarks: Andrea Pfeifer, Ph.D., CEO of AC Immune

Perspectives of disease-modification in Parkinson’s disease

Presenter: Werner Poewe, M.D. (Medical University of Innsbruck)

Time: 8:50 – 9:10 am CET

Targeting alpha-synuclein in early Parkinson’s disease: ACI-7104.056 in the Phase 2 trial VacSYn

Presenter: Günther Staffler, Ph.D. (AC Immune)

Time: 9:10 – 9:25 am CET

Precision Prevention for Alzheimer’s disease

Presenter: Philip Scheltens, M.D., Ph.D. (EQT Life Sciences, Amsterdam University Medical Center) Time: 9:25 – 9:50 am CET

The first active immunotherapy for AD prevention: ACI-35.030/JNJ2056 in the Phase 2b Retain study

Presenter: Lennert Steukers, Ph.D. (Johnson & Johnson Innovative Medicine)

Time: 9:50 – 10:05 am CET

Anti-Abeta active immunotherapy in early AD and DSAD: ACI-24.060 in the Phase 1b/2 ABATE study

Presenter: Anke Post, M.D., Ph.D. (AC Immune)

Time: 10:05 – 10:20 am CET

The presentations will be followed by a Q&A session, and a replay of the Industry Symposium will be available on the Events page of AC Immune’s website after the event.



Oral Presentations



Morphomer® small molecules targeting Tau for the treatment of Alzheimer’s disease

Presenter: Nicolas Preitner, Ph.D. (AC Immune)

Session: Translational Drug Development and Experimental Models

Location: Hall C

Date/Time: Saturday, April 5, 2025, at 16:40 – 16:55 pm CET

Development of Morphomer-antibody drug conjugates – a new class of drugs for neurodegenerative diseases

Virtual On-Demand Oral Presentation - Virtual OO - 186

Presenter: Nampally Sreenivasachary, Ph.D. (AC Immune)

Discovery and optimization of therapeutic small molecules targeting alpha-synuclein aggregation

Virtual On-Demand Oral Presentation - Virtual OO - 187

Presenter: Elpida Tsika, Ph.D. (AC Immune)



Poster Presentations



Defining optimal thresholds for time-to-event endpoints for Parkinson’s disease clinical trials

Poster on Board - SHIFT 02-066

Presenter: Nicolas Sanchez (AC Immune)



Presentations and posters by our collaboration partners



Antibodies generated by JNJ-64042056, an active anti-pTau immunotherapy, in clinical trial ACI-35-1802 can block Tau seeding in neurons

Presenter: Clara Theunis, Ph.D. (Johnson & Johnson Innovative Medicine)

Session: Abeta & Tau Immunotherapies

Location: Hall E

Date/Time: Saturday, April 5, 2025, at 12:40 – 12:55 am CET

Immunization with JNJ-64042056 generates antibodies in non-human primates that inhibit Tau aggregation in a neuronal Tau seeding model

Poster on Board - SHIFT 02-636

Presenter: Bruno Vasconcelos, Ph.D. (Johnson & Johnson Innovative Medicine)

About AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

For further information, please contact:

SVP, Investor Relations & Corporate Communications



Gary Waanders, Ph.D., MBA

AC Immune

Phone: 1

Email:



U.S. Investors



Christina Tartaglia

Precision AQ

Phone:

Email:







International Media



Chris Maggos

Cohesion Bureau

Phone:

Email:
 

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Attachment



EN
25/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AC IMMUNE SA

 PRESS RELEASE

AC Immune Reports Further Positive Interim Results from Phase 2 Trial ...

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizationsRepeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titersACI-7104.056 is well tol...

 PRESS RELEASE

AC Immune Announces Upcoming Presentations and Industry Symposium on A...

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseasesMultiple presentations at the International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2025) showcasing the diversity of the company’s precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC...

 PRESS RELEASE

AC Immune Reports Full Year 2024 Financial Results and Provides a Corp...

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercializationACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome (DS) cohort; further interim results in Alzheimer’s disease (AD) and DS expected in 2025Enrollment progress in JNJ-20...

 PRESS RELEASE

AC Immune to Participate in Upcoming Investor Conferences

AC Immune to Participate in Upcoming Investor Conferences AC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company's management will participate in the following investor conferences in March: Leerink Partners 2025 Global Healthcare Conference,Management will participate in investor meetings on March 10, 2025Barclays 27th Annual Global Healthcare Conference,Management will participate ...

 PRESS RELEASE

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of A...

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drugNo cases of amyloid-related imaging abnormalities observed in this study populationBased upon these findings, AC Immune plans to open the high-dose cohort in ABATE in individuals with Down syndrome Lausanne, Switzerland, December 10, 2024 – AC Immune SA (NASDAQ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch